ClinicalTrials.gg
CompletedNCT00839072Updated Apr 27, 2012Results posted

Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers

A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy, sponsored by Labopharm Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations

Read the detailed description

The bioavailability of once-daily trazodone extended-release 300 mg caplets (test product) and trazodone immediate-release 100 mg tablets administered q8h (reference product) will be compared in healthy adult volunteers in a randomized, crossover fashion. Morning doses will be administered after an overnight fast. Blood samples will be collected predose and at pre-defined times over 72 hours following the morning dose. Pharmacokinetic parameters will be analyzed using ANOVA. Comparative bioavailability will be assessed on the basis of the ratio of least-squares means and/or 90% confidence interval criteria.

02

Conditions studied

  • Healthy

Keywords

  • bioavailability
  • pharmacokinetics
  • healthy
  • crossover
  • trazodone
03

In context

Lead sponsor

Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability for entire study period and willingness to adhere to protocol requirements as evidenced by signed
  • Male or female volunteer, aged between 18 and 45 years inclusively
  • ≥20 and \<30 kg/m2
  • Minimum body weight: 60 kg
  • Clinical laboratory values within normal range, or without clinical significance
  • Healthy according to medical history, clinical laboratory results and physical examination
  • Nonsmoker or ex-smoker

Exclusion criteria

Exclusion Criteria:

  • Significant history of to trazodone or any related products, or severe hypersensitivity reactions to any drugs
  • Presence or history of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects
  • Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
  • Suicidal tendency, history of or disposition to seizures, state of confusion, psychiatric disease
  • Use of MAO inhibitors within 28 days of day 1 of the study
  • Presence of significant heart disease or disorder according to
  • Seated systolic blood pressure lower than 90 or over 140 mmHg or diastolic blood pressure lower than 50 or over 90 mmHg at screening
  • Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (>3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  • Any clinically significant illness in the previous 28 days before day 1 of this study
  • Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, and antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, , phenytoin, and rifampin), in the previous 28 days before day 1 of this study
  • Females who are pregnant according to a positive serum pregnancy test, or are lactating
  • Females of who refuse to use an acceptable method of from the screening visit and throughout the study
  • Volunteers who took an product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study
  • Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician
  • Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc) in the previous 56 days before day 1 of the study
  • Positive urine screening for drugs of abuse
  • Any history of tuberculosis and/or prophylaxis for tuberculosis
  • Positive results to HIV, , or anti- tests
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Trazodone Contramid OAD

    Drug: Trazodone HCl

  • Active comparator
    Desyrel

    Drug: Trazodone HCl

Interventions

  • 100 mg immediate-release tablet, dosing q8h

  • 300 mg extended-release caplet, single dose

    Also known as: Oleptro

06

What researchers measure

Primary outcomes

  1. Bioequivalence Based on Cmax

    Cmax = Maximum plasma concentration Measured in nanograms per millilitre (ng/mL)

    Time frame: 72 hours post-dose

  2. Bioequivalence Based on AUCT

    AUCT = Area under the concentration-time curve from 0 to the time of the last quantifiable concentration

    Time frame: 72 hours post-dose

  3. Bioequivalence Based on AUC∞

    AUC∞ = Area under the concentration-time curve extrapolated to infinity

    Time frame: 72 hours post-dose

Secondary outcomes

  1. Time of Maximum Measured Plasma Concentration (Tmax)

    Time frame: 72 hours post-dose

  2. Apparent Terminal Elimination Half-Life [T½el]

    The elimination half-life (T½el) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.

    Time frame: 72 hours post-dose

  3. Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]

    Time frame: 24 hours

07

Results

Posted Aug 16, 2010

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First
Started1212
Completed1011
Not completed21
Withdrew: Withdrawal by subject10
Withdrew: Adverse event11
Washout Period of 7 Days
Participant flow — Washout Period of 7 Days
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First
Started1011
Completed1011
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First
Started1011
Completed911
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryBioequivalence Based on Cmax

Cmax = Maximum plasma concentration Measured in nanograms per millilitre (ng/mL)

Time frame:
72 hours post-dose
Reported as:
Mean · ng/mL
Bioequivalence Based on Cmax
ng/mLTrazodone Contramid® OADDesyrel®
Bioequivalence Based on Cmax1060.8 ± 366.61743.3 ± 470.1
Statistical analysis
  • Trazodone Contramid® OAD vs Desyrel® · Ratio of the mean: 59.66 · 90% CI 50.99 to 69.81Trazodone Contramid® OAD/Desyrel®
PrimaryBioequivalence Based on AUCT

AUCT = Area under the concentration-time curve from 0 to the time of the last quantifiable concentration

Time frame:
72 hours post-dose
Reported as:
Mean · ng*h/mL
Bioequivalence Based on AUCT
ng*h/mLTrazodone Contramid® OADDesyrel®
Bioequivalence Based on AUCT29180.6 ± 10557.136002.4 ± 9636.4
Statistical analysis
  • Trazodone Contramid® OAD vs Desyrel® · Ratio of the mean: 78.55 · 90% CI 69.70 to 88.51Trazodone Contramid® OAD/Desyrel®
PrimaryBioequivalence Based on AUC∞

AUC∞ = Area under the concentration-time curve extrapolated to infinity

Time frame:
72 hours post-dose
Reported as:
Mean · ng*h/mL
Bioequivalence Based on AUC∞
ng*h/mLTrazodone Contramid® OADDesyrel®
Bioequivalence Based on AUC∞30913.7 ± 11904.837273.4 ± 10738.5
Statistical analysis
  • Trazodone Contramid® OAD vs Desyrel® · Ratio of the mean: 80.05 · 90% CI 70.67 to 90.68Trazodone Contramid® OAD/Desyrel®
SecondaryTime of Maximum Measured Plasma Concentration (Tmax)
Time frame:
72 hours post-dose
Reported as:
Median · hours
Time of Maximum Measured Plasma Concentration (Tmax)
hoursTrazodone Contramid® OADDesyrel®
Time of Maximum Measured Plasma Concentration (Tmax)6.00 (1.05 to 24.00)9.50 (0.33 to 21.00)
SecondaryApparent Terminal Elimination Half-Life [T½el]

The elimination half-life (T½el) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.

Time frame:
72 hours post-dose
Reported as:
Mean · Hours
Apparent Terminal Elimination Half-Life [T½el]
HoursTrazodone Contramid® OADDesyrel®
Apparent Terminal Elimination Half-Life [T½el]14.37 ± 4.3112.16 ± 3.51
SecondaryArea Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]
Time frame:
24 hours
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]
ng*h/mLTrazodone Contramid® OADDesyrel®
Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]16885.8 ± 5453.022512.8 ± 5045.2

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trazodone Contramid® OAD—0/23 (0%)20/23 (87%)
Desyrel®—0/22 (0%)21/22 (95.5%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTrazodone Contramid® OADDesyrel®
SomnolenceNervous system disorders17/2320/22
DizzinessNervous system disorders2/239/22
NauseaGastrointestinal disorders2/236/22
FatigueGeneral disorders6/234/22
HeadacheNervous system disorders5/233/22
Dry mouthGastrointestinal disorders2/233/22
PalpitationsCardiac disorders0/232/22
Dry eyesEye disorders1/232/22
Ocular hyperaemiaEye disorders0/232/22
DyspepsiaGastrointestinal disorders0/232/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years24
>=65 years0
Age Continuous
Age Continuous(years)Entire Study Population
Mean35 ± 6
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female14
Male10
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
Canada24
08

Study locations

1 site
  • Algorithme Pharma Inc.
    Laval, Quebec H7V 4B3, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2009
First posted
Feb 9, 2009
Start
Feb 2009
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results first posted
Aug 16, 2010
Last update
Apr 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00839072
Lead sponsor
Labopharm Inc.
Collaborators
Algorithme Pharma Inc
Responsible party
Sponsor
First posted
Feb 9, 2009
Start date
Feb 2009
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Aug 16, 2010
Last update
Apr 27, 2012

Study contacts

Eric Sicard, MD
principal investigator · Algorithme Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion